Furthermore, we examined the mechanisms by which ADAM17/EGFR/MAPK/ERK pathway contributed to miR-145-induced inhibition on glioma proliferation, invasion, and angiogenesis after transfection of miR-145. The gene discussed is ADAM17; the disease is central nervous system cancer.